BIIB
Price
$123.53
Change
+$2.60 (+2.15%)
Updated
May 2 closing price
Capitalization
31.34B
81 days until earnings call
SNY
Price
$55.44
Change
+$1.34 (+2.48%)
Updated
May 2 closing price
Capitalization
122.61B
89 days until earnings call
Ad is loading...

BIIB vs SNY

Header iconBIIB vs SNY Comparison
Open Charts BIIB vs SNYBanner chart's image
Biogen
Price$123.53
Change+$2.60 (+2.15%)
Volume$1.46M
Capitalization31.34B
Sanofi ADS
Price$55.44
Change+$1.34 (+2.48%)
Volume$2.25M
Capitalization122.61B
BIIB vs SNY Comparison Chart
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIIB vs. SNY commentary
May 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Hold and SNY is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 03, 2025
Stock price -- (BIIB: $123.53 vs. SNY: $55.44)
Brand notoriety: BIIB: Notable vs. SNY: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 82% vs. SNY: 73%
Market capitalization -- BIIB: $31.34B vs. SNY: $122.61B
BIIB [@Pharmaceuticals: Major] is valued at $31.34B. SNY’s [@Pharmaceuticals: Major] market capitalization is $122.61B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileSNY’s FA Score has 1 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • SNY’s FA Score: 1 green, 4 red.
According to our system of comparison, SNY is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 4 TA indicator(s) are bullish while SNY’s TA Score has 5 bullish TA indicator(s).

  • BIIB’s TA Score: 4 bullish, 5 bearish.
  • SNY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SNY is a better buy in the short-term than BIIB.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а +3.95% price change this week, while SNY (@Pharmaceuticals: Major) price change was +5.96% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.43%. For the same industry, the average monthly price growth was +3.13%, and the average quarterly price growth was -5.44%.

Reported Earning Dates

BIIB is expected to report earnings on Jul 23, 2025.

SNY is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+2.43% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNY($123B) has a higher market cap than BIIB($31.3B). BIIB has higher P/E ratio than SNY: BIIB (26.95) vs SNY (20.80). SNY YTD gains are higher at: 14.949 vs. BIIB (-19.219). SNY has higher annual earnings (EBITDA): 12.6B vs. BIIB (2.04B). SNY has more cash in the bank: 8.98B vs. BIIB (1.05B). BIIB has less debt than SNY: BIIB (7.34B) vs SNY (18.4B). SNY has higher revenues than BIIB: SNY (46.4B) vs BIIB (9.84B).
BIIBSNYBIIB / SNY
Capitalization31.3B123B25%
EBITDA2.04B12.6B16%
Gain YTD-19.21914.949-129%
P/E Ratio26.9520.80130%
Revenue9.84B46.4B21%
Total Cash1.05B8.98B12%
Total Debt7.34B18.4B40%
FUNDAMENTALS RATINGS
BIIB vs SNY: Fundamental Ratings
BIIB
SNY
OUTLOOK RATING
1..100
415
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
12
Undervalued
PROFIT vs RISK RATING
1..100
10036
SMR RATING
1..100
6775
PRICE GROWTH RATING
1..100
6451
P/E GROWTH RATING
1..100
9679
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SNY's Valuation (12) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (87) in the Biotechnology industry. This means that SNY’s stock grew significantly faster than BIIB’s over the last 12 months.

SNY's Profit vs Risk Rating (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (100) in the Biotechnology industry. This means that SNY’s stock grew somewhat faster than BIIB’s over the last 12 months.

BIIB's SMR Rating (67) in the Biotechnology industry is in the same range as SNY (75) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to SNY’s over the last 12 months.

SNY's Price Growth Rating (51) in the Pharmaceuticals Major industry is in the same range as BIIB (64) in the Biotechnology industry. This means that SNY’s stock grew similarly to BIIB’s over the last 12 months.

SNY's P/E Growth Rating (79) in the Pharmaceuticals Major industry is in the same range as BIIB (96) in the Biotechnology industry. This means that SNY’s stock grew similarly to BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBSNY
RSI
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
40%
Momentum
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 2 days ago
56%
MACD
ODDS (%)
Bullish Trend 2 days ago
46%
Bullish Trend 2 days ago
50%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
53%
Bullish Trend 2 days ago
55%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
50%
Advances
ODDS (%)
Bullish Trend 4 days ago
53%
Bullish Trend 4 days ago
53%
Declines
ODDS (%)
Bearish Trend 18 days ago
69%
Bearish Trend 18 days ago
48%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
40%
Aroon
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
42%
View a ticker or compare two or three
Ad is loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
STIM4.580.12
+2.69%
Neuronetics
AHH6.920.14
+2.06%
Armada Hoffler Properties
GBTG6.880.12
+1.78%
Global Business Travel Group
FOX46.170.30
+0.65%
Fox Corp
MSGM2.52-0.02
-0.79%
Motorsport Games

SNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNY has been loosely correlated with SNYNF. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then SNYNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNY
1D Price
Change %
SNY100%
+2.48%
SNYNF - SNY
61%
Loosely correlated
N/A
GSK - SNY
49%
Loosely correlated
+0.83%
NVS - SNY
47%
Loosely correlated
+2.66%
AZN - SNY
46%
Loosely correlated
+2.74%
PFE - SNY
44%
Loosely correlated
+1.13%
More